Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
ACZ885-IL-1 beta inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
NCT03447769 CANOPY-A (CACZ885T2301)
Adjuvant NSCLC
Phase 3
1500
Disease free survival (primary), overall survival (key secondary)
Canakinumab 200mg q3w sc for 18 cycles
Placebo q3w sc for 18 cycles
Patients with:
High-risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB (T>5cm N2)) after complete
resection and standard of care adjuvant cisplatin-based chemotherapy
All histologies
Read-out Milesstone(s)
2023
Publication
TBD
NCT03626545 CANOPY-2 (CACZ885V2301)
2nd/3rd Line Non-small cell lung cancer (NSCLC)
Phase 3
240
Safety run-in part: Incidence of dose limiting toxicities
Double-blind, randomized, placebo-controlled part: Overall Survival
Canakinumab in combination with docetaxel
Canakinumab matching-placebo in combination with docetaxel
Patients with:
Stage IIIB or IV NSCLC without EGFR, ALK, ROS-1 or B-RAF mutation
Previously treated with platinum therapy and PD(L)1-inhibitor
March-2021 (Actual)
Abstract submitted to ESMO, manuscript in progress.
97 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation